$10.43 Million in Sales Expected for Portola Pharmaceuticals Inc (PTLA) This Quarter
Equities analysts predict that Portola Pharmaceuticals Inc (NASDAQ:PTLA) will report $10.43 million in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Portola Pharmaceuticals’ earnings. The highest sales estimate is $10.69 million and the lowest is $10.16 million. Portola Pharmaceuticals posted sales of $9.80 million during the same quarter last year, which suggests a positive year-over-year growth rate of 6.4%. The business is expected to announce its next quarterly earnings report on Wednesday, February 27th.
On average, analysts expect that Portola Pharmaceuticals will report full year sales of $35.41 million for the current fiscal year, with estimates ranging from $34.99 million to $35.73 million. For the next year, analysts expect that the company will post sales of $97.16 million, with estimates ranging from $61.31 million to $138.41 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that cover Portola Pharmaceuticals.
Portola Pharmaceuticals (NASDAQ:PTLA) last released its earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($1.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.54) by $0.46. The business had revenue of $14.20 million during the quarter, compared to the consensus estimate of $7.10 million. Portola Pharmaceuticals had a negative net margin of 1,020.52% and a negative return on equity of 135.08%. The company’s revenue for the quarter was up 270.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.41) EPS.
In other Portola Pharmaceuticals news, Director Jeffrey W. Bird purchased 137,563 shares of Portola Pharmaceuticals stock in a transaction that occurred on Tuesday, August 21st. The stock was acquired at an average price of $25.17 per share, with a total value of $3,462,460.71. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Jeffrey W. Bird purchased 390,000 shares of Portola Pharmaceuticals stock in a transaction that occurred on Thursday, August 23rd. The stock was acquired at an average cost of $25.84 per share, with a total value of $10,077,600.00. The disclosure for this purchase can be found here. Company insiders own 4.60% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Raymond James & Associates grew its position in Portola Pharmaceuticals by 102.9% in the 2nd quarter. Raymond James & Associates now owns 40,302 shares of the biopharmaceutical company’s stock valued at $1,522,000 after purchasing an additional 20,441 shares during the period. Russell Investments Group Ltd. grew its position in Portola Pharmaceuticals by 67.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 129,000 shares of the biopharmaceutical company’s stock valued at $4,872,000 after purchasing an additional 52,148 shares during the period. Harvey Capital Management Inc. grew its position in Portola Pharmaceuticals by 17.3% in the 3rd quarter. Harvey Capital Management Inc. now owns 184,672 shares of the biopharmaceutical company’s stock valued at $4,917,000 after purchasing an additional 27,192 shares during the period. MetLife Investment Advisors LLC grew its position in Portola Pharmaceuticals by 16.9% in the 2nd quarter. MetLife Investment Advisors LLC now owns 29,932 shares of the biopharmaceutical company’s stock valued at $1,131,000 after purchasing an additional 4,318 shares during the period. Finally, Sector Gamma AS grew its position in Portola Pharmaceuticals by 49.0% in the 2nd quarter. Sector Gamma AS now owns 200,800 shares of the biopharmaceutical company’s stock valued at $7,584,000 after purchasing an additional 66,000 shares during the period. 93.85% of the stock is owned by institutional investors and hedge funds.
NASDAQ:PTLA opened at $20.20 on Friday. The company has a market cap of $1.36 billion, a price-to-earnings ratio of -4.20 and a beta of 2.04. The company has a debt-to-equity ratio of 1.21, a current ratio of 6.61 and a quick ratio of 6.51. Portola Pharmaceuticals has a fifty-two week low of $18.18 and a fifty-two week high of $56.70.
About Portola Pharmaceuticals
Portola Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics that could advance the fields of thrombosis and other hematologic diseases. The company's two FDA-approved medicines are Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo), an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of VTE in adult patients hospitalized for an acute medical illness.
Read More: NASDAQ
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.